Donor and Recipient Hepatitis C Status Does Not Affect Rejection in Thoracic Transplantation |
| |
| Affiliation: | 1. Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio;2. Section of Biostatistics, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio;3. Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio;4. Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio |
| |
| Abstract: | BackgroundDonors with hepatitis C virus (HCV) have expanded the donor pool for heart and lung transplantation, but concerns have arisen about rejection. We examined the incidence of rejection after heart and lung transplantation in recipients of HCV-positive donors as well as HCV-positive recipients.MethodsAdults undergoing heart and lung transplantation from March 31, 2015 to December 31, 2019 were identified in the United Network for Organ Sharing/Organ Transplantation and Procurement Network Standard Transplant Analysis and Research file. Patients were stratified as donor–recipient HCV negative, donor positive, and recipient positive. Comparative statistics and a multilevel logistic regression model were used.ResultsMeeting the criteria were 10 624 heart transplant recipients. Donor-positive recipients were significantly associated with older age, blood group O, and shorter waitlist time. No significant differences existed with regards to treatment for rejection in the first year (negative, 19.5%; donor positive, 22.3%; recipient positive, 19.5%; P = .45) or other outcomes. On regression analysis HCV status was not associated with treated rejection; however center variability was significantly associated with treated rejection (median odds ratio, 2.18). Similarly, 9917 lung transplant recipients were identified. Donor-positive recipients were more commonly White and had obstructive disease and lower lung allocation scores. Both unadjusted (negative, 22.1%; donor positive, 23.0%; recipient positive, 18.6%; P = .43) and adjusted analyses failed to demonstrate a significant association between HCV status and treatment for rejection, whereas center variability remained significantly associated with treatment for rejection (median odds ratio, 2.41).ConclusionsUse of HCV donors has expanded the donor pool for heart and lung transplantation. HCV donor status was not associated with treatment for rejection in the first year, but center variability played a role in the incidence and treatment of rejection. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
